Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $25,940.85 in Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 689 shares of the firm’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $25,940.85. Following the completion of the transaction, the insider now owns 110,849 shares in the company, valued at $4,173,464.85. This represents a 0.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Dennis Cho also recently made the following trade(s):

• On Wednesday, April 2nd, Dennis Cho sold 124 shares of Twist Bioscience stock. The stock was sold at an average price of $38.73, for a total transaction of $4,802.52.
• On Thursday, March 20th, Dennis Cho sold 230 shares of Twist Bioscience stock. The shares were sold at an average price of $41.68, for a total value of $9,586.40.
• On Friday, March 14th, Dennis Cho sold 92 shares of Twist Bioscience stock. The shares were sold at an average price of $40.05, for a total value of $3,684.60.
• On Thursday, March 6th, Dennis Cho sold 277 shares of Twist Bioscience stock. The stock was sold at an average price of $40.91, for a total transaction of $11,332.07.

Twist Bioscience Stock Down 0.3 %

TWST stock opened at $32.67 on Friday. The company’s 50 day moving average is $38.81 and its 200 day moving average is $43.74. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -9.66 and a beta of 2.54. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 1-year low of $31.56 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The company had revenue of $92.79 million for the quarter, compared to analysts’ expectations of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of TWST. First Light Asset Management LLC bought a new stake in Twist Bioscience in the 4th quarter worth approximately $56,984,000. Marshall Wace LLP boosted its stake in shares of Twist Bioscience by 15,927.8% in the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company’s stock valued at $39,319,000 after purchasing an additional 840,828 shares in the last quarter. ARK Investment Management LLC grew its holdings in shares of Twist Bioscience by 11.5% during the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company’s stock valued at $245,045,000 after purchasing an additional 645,730 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in Twist Bioscience by 54.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after purchasing an additional 532,040 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in Twist Bioscience by 80.2% during the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after buying an additional 302,884 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on TWST shares. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Guggenheim reissued a “buy” rating and set a $50.00 target price on shares of Twist Bioscience in a report on Tuesday. The Goldman Sachs Group reduced their price target on Twist Bioscience from $55.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday. Robert W. Baird dropped their price objective on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, JPMorgan Chase & Co. reduced their target price on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.